Browse > Article
http://dx.doi.org/10.5806/AST.2021.34.2.37

Development of Jaspine B analysis using LC-MS/MS and its application: Dose-independent pharmacokinetics of Jaspine B in rats  

Song, Im-Sook (BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, Vessel-Organ Interaction Research Center (VOICE), College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Jeon, Ji-Hyeon (BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, Vessel-Organ Interaction Research Center (VOICE), College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lee, Jihoon (BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, Vessel-Organ Interaction Research Center (VOICE), College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lim, Dong Yu (College of Pharmacy, Dankook University)
Lee, Chul Haeng (College of Pharmacy, Dankook University)
Lee, Dongjoo (College of Pharmacy, Ajou University)
Choi, Min-Koo (College of Pharmacy, Dankook University)
Publication Information
Analytical Science and Technology / v.34, no.2, 2021 , pp. 37-45 More about this Journal
Abstract
A rapid and simple LC-MS/MS analytical method in determining Jaspine B has been developed and validated in rat plasma. The standard curve value was 25 - 5000 ng/mL and the linearity, inter-day and intra-day accuracy and precision were within 15.0 % of relative standard deviation (RSD). The mean recoveries of Jaspine B ranged from 87.5 % to 91.2 % with less than 3.70 % RSD and the matrix effects ranged from 91.1 % to 108.2 % with less than 2.6 % RSD. The validated LC-MS/MS analytical method of Jaspine B was successfully applied to investigate the dose-escalated pharmacokinetic study of Jaspine B in rats following an intravenous injection of Jaspine B at a dose range of 1 - 10 mg/kg. The initial plasma concentrations and area under plasma concentration curves showed a good correlation with intravenous Jaspine B dose, indicating the dose independent pharmacokinetics of Jaspine B in rats. In conclusion, this analytical method for Jaspine B can be easily applied in the bioanalysis and pharmacokinetic studies of Jaspine B, including its administration at multiple therapeutic doses, or for making pharmacokinetic comparisons for the oral formulations of Jaspine B in small experimental animals as well as in vivo pharmacokinetic-pharmacodynamic correlation studies.
Keywords
jaspine B; liquid chromatography-tandem mass spectrometry; pharmacokinetics; rat; dose escalation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. O. Lee, J. S. Kim, M. S. Lee and H. J. Lee, BMC Cancer, 16, 701 (2016).   DOI
2 S. A. Morad and M. C. Cabot, Nature Reviews Cancer, 13(1), 51-65 (2013).   DOI
3 D. Shida, K. Takabe, D. Kapitonov, S. Milstien and S. Spiegel, Current Drug Targets, 9(8), 662-673 (2008).   DOI
4 M. Bektas, P. S. Jolly, C. Muller, J. Eberle, S. Spiegel and C. C. Geilen, Oncogene, 24(1), 178-187 (2005).   DOI
5 K. J. French, R. S. Schrecengost, B. D. Lee, Y. Zhuang, S. N. Smith, J. L. Eberly, J. K. Yun and C. D. Smith, Cancer Research, 63(18), 5962-5969 (2003).
6 K. R. Johnson, K. Y. Johnson, H. G. Crellin, B. Ogretmen, A. M. Boylan, R. A. Harley and L. M. Obeid, Journal of Histochemistry and Cytochemistry, 53(9), 1159-1166 (2005).   DOI
7 S. Sobue, T. Iwasaki, C. Sugisaki, K. Nagata, R. Kikuchi, M. Murakami, A. Takagi, T. Kojima, Y. Banno, Y. Akao, Y. Nozawa, R. Kannagi, M. Suzuki, A. Abe, T. Naoe and T. Murate, Leukemia, 20(11), 2042-2046 (2006).
8 B. Haefner, Drug Discovery Today, 8(12), 536-544 (2003).   DOI
9 I. Kuroda, M. Musman, I. I. Ohtani, T. Ichiba, J. Tanaka, D. G. Gravalos and T. Higa, Journal of Natural Products, 65(10), 1505-1506 (2002).   DOI
10 Y. Yoshimitsu, S. Oishi, J. Miyagaki, S. Inuki, H. Ohno and N. Fujii, Bioorganic & Medicinal Chemistry, 19(18), 5402-5408 (2011).   DOI
11 H. Yoo, Y. S. Lee, S. Lee, S. Kim and T. Y. Kim, Phytotherapy Research, 26(12), 1927-1933 (2012).   DOI
12 B. A. Stoica, V. A. Movsesyan, P. M. Lea and A. I. Faden, Molecular and Cellular Neuroscience, 22(3), 365-382 (2003).   DOI
13 V. Garcia, P. Le Faouder, A. Dupuy, T. Levade, S. Ballereau and Y. Genisson, Chemistry & Biodiversity, 12(7), 1115-1125 (2015).   DOI
14 F. Cingolani, F. Simbari, J. L. Abad, M. Casasampere, G. Fabrias, A. H. Futerman and J. Casas, Journal of Lipid Research, 58(8), 1500-1513 (2017).   DOI
15 J. Lee, K. Choi, M. Kwon, D. Lee, M. K. Choi and I. S. Song, Journal of Life Science, 26(12), 101-109 (2016).   DOI
16 Y. Kwon, J. Song, H. Bae, W. J. Kim, J. Y. Lee, G. H. Han, S. K. Lee and S. Kim, Marine Drugs, 13(2), 824-837 (2015).   DOI
17 M. Kwon, D. Y. Lim, C. H. Lee, J. H. Jeon, M. K. Choi and I. S. Song, Pharmaceutics, 12(9) 882 (2020).   DOI
18 Y. Salma, E. Lafont, N. Therville, S. Carpentier, M. J. Bonnafe, T. Levade, Y. Genisson and N. Andrieu-Abadie, Biochemical Pharmacology, 78(5), 477-485 (2009).   DOI
19 J. H. Jeon, J. Lee, M. K. Choi and I. S. Song, Archives of Pharmacal Research, 43(12), 1335-1346 (2020).   DOI